加载中
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
前收盘价
US$1.41
+US$0.05 · +3.68%
盘中时间采用ET。市场数据可能有所延迟。
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
日内区间
当前US$1.41
52周区间
当前US$1.41
盘中时间采用ET。市场数据可能有所延迟。
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
日内区间
当前US$1.41
52周区间
当前US$1.41
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7038.7万 USD | 5934.5万 USD | 7014.3万 USD | 1.39亿 USD | 1.05亿 USD |
| 销货成本 | 933.8万 USD | 1628.8万 USD | 1280.9万 USD | 3803.3万 USD | 2220.9万 USD |
| 毛利 | 6104.9万 USD | 4305.7万 USD | 5733.4万 USD | 1.01亿 USD | 8254.5万 USD |
| 研究与开发 | 5230.7万 USD | 4626.3万 USD | 5888.5万 USD | 8009.9万 USD | 5591.9万 USD |
| 销售、一般及管理费用 | 4707.4万 USD | 5514.8万 USD | 5325万 USD | 5217.2万 USD | 4932.3万 USD |
| 营业费用 | 9938.1万 USD | 1.02亿 USD | 1.25亿 USD | 1.35亿 USD | 1.05亿 USD |
| 利息收入 | 262.5万 USD | 367万 USD | 417.2万 USD | 144.1万 USD | 45.9万 USD |
| 利息支出 | 481.3万 USD | — | — | — | — |
| 折旧和摊销 | 524.8万 USD | 494.6万 USD | 992.3万 USD | 1025.1万 USD | 594.7万 USD |
| 营业利润 | −3833.2万 USD | −5851.9万 USD | −6806.9万 USD | −3488.1万 USD | −2269.7万 USD |
| 净利润 | −4397.4万 USD | −6527.6万 USD | −7624万 USD | −3359.2万 USD | −2127.9万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
